Stay updated on Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.

Latest updates to the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check34 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check76 days agoChange DetectedThe web page has been updated to version 2.15.0, replacing the previous version 2.14.4.SummaryDifference1.0%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
Stay in the know with updates to Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.